[go: up one dir, main page]

MD20040296A - Pharmaceutical composition containing oxcarbazepin with prolonged release of the active ingredient - Google Patents

Pharmaceutical composition containing oxcarbazepin with prolonged release of the active ingredient Download PDF

Info

Publication number
MD20040296A
MD20040296A MDA20040296A MD20040296A MD20040296A MD 20040296 A MD20040296 A MD 20040296A MD A20040296 A MDA20040296 A MD A20040296A MD 20040296 A MD20040296 A MD 20040296A MD 20040296 A MD20040296 A MD 20040296A
Authority
MD
Moldova
Prior art keywords
oxcarbazepin
active ingredient
prolonged release
pharmaceutical composition
composition containing
Prior art date
Application number
MDA20040296A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Хансхерманн ФРАНКЕ
Петер ЛЕННАРТЦ
Original Assignee
Деситин Арцнеймитель Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10224170A external-priority patent/DE10224170A1/en
Priority claimed from DE10250566A external-priority patent/DE10250566A1/en
Application filed by Деситин Арцнеймитель Гмбх filed Critical Деситин Арцнеймитель Гмбх
Priority claimed from PCT/EP2003/005116 external-priority patent/WO2003101430A1/en
Publication of MD20040296A publication Critical patent/MD20040296A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the pharmaceutical compositions, especially for oral administration, containing therapeutically efficient quantity of oxcarbazepin with prolonged release of the active ingredient in vitro.
MDA20040296A 2002-05-31 2003-05-15 Pharmaceutical composition containing oxcarbazepin with prolonged release of the active ingredient MD20040296A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10224177 2002-05-31
DE10224170A DE10224170A1 (en) 2002-05-31 2002-05-31 Retarded release pharmaceutical composition, obtained without use of organic solvents or water by densifying mixture of active agent and retarding polymer in heated rollers
DE10250566A DE10250566A1 (en) 2002-05-31 2002-10-30 Pharmaceutical composition containing oxcarbazepine, having suitable release profile for once-daily administration in treatment of epilepsy, pain or alcohol withdrawal symptoms
PCT/EP2003/005116 WO2003101430A1 (en) 2002-05-31 2003-05-15 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release

Publications (1)

Publication Number Publication Date
MD20040296A true MD20040296A (en) 2005-05-31

Family

ID=40600478

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20040296A MD20040296A (en) 2002-05-31 2003-05-15 Pharmaceutical composition containing oxcarbazepin with prolonged release of the active ingredient

Country Status (4)

Country Link
KR (1) KR20050010843A (en)
AT (1) ATE429905T1 (en)
DE (1) DE50311479D1 (en)
MD (1) MD20040296A (en)

Also Published As

Publication number Publication date
ATE429905T1 (en) 2009-05-15
DE50311479D1 (en) 2009-06-10
KR20050010843A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
PL370292A1 (en) Formulations for oral administration of active compounds
BG66093B1 (en) Controlled release compositions comprising nimesulide
IL153297A0 (en) Compounds and compositions for delivering active agents
UA96449C2 (en) Stable laquinimod preparations
MXPA03007857A (en) Compounds and compositions for delivering active agents.
TW200621317A (en) Pharmaceutical composition
MXPA01008611A (en) Compounds and compositions for delivering active agents.
AU2274201A (en) Compounds and compositions for delivering active agents
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MY157790A (en) Trazodone composition for once a day administration
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
EP2279732A3 (en) Compounds and compositions for delivering active agents
BR0311327A (en) Oxcarbazepine-containing pharmaceutical composition with sustained release of an active ingredient
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
PL377683A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
AU2003202550A1 (en) Pharmaceutical formulations with modified release
MD20040296A (en) Pharmaceutical composition containing oxcarbazepin with prolonged release of the active ingredient
SE0203817D0 (en) New composition
WO2005062874A3 (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)